Blinatumomab promising for treatment of aggressive infant leukemia with 81.6% disease-free survival rate: NEJM

Netherlands: In a study conducted by researchers, Blinatumomab, a bispecific T-cell engager molecule, to be safe and efficacious for infants with newly diagnosed KMT2A- rearranged acute lymphoblastic leukemia (ALL). The study was published in NEJM Medicine.
KMT2A-rearranged acute lymphoblastic leukemia (ALL) in neonates is a deadly disease with a three-year event-free survival rate of less than 40%. Relapses occur in two-thirds of patients within a year and 90% within 2 years of diagnosis. The study aimed to study the safety and efficacy of the Blinatumomab molecule targeting CD19 in infants with KMT2A-rearranged ALL.
The study administered one postinduction course of blinatumomab to 30 infants with KMT2A-rearranged ALL, alongside Interfant-06 chemotherapy. The primary endpoint was safety, and minimal residual disease was measured by polymerase chain reaction. Data on adverse events were collected and compared with historical control data from the Interfant-06 trial.
The following clinical findings were revealed in the study:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.